Barclays raised the firm’s price target on McKesson (MCK) to $1,050 from $960 and keeps an Overweight rating on the shares. The firm expects the stock to “remain in favor” as investors seek “pockets of safety within healthcare,” but notes McKesson is now trading at a 15% premium to its three-year average.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK: